Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Randox Laboratories' KRAS/BRAF/PIK3CA Array

Premium

Randox Laboratories this week launched its KRAS/BRAF/PIK3CA Array. The company said that clinicians can use the chip to select appropriate patients for colorectal cancer patients undergoing anti-EGFR therapy.

The KRAS/BRAF/PIK3CA Array is designed for the qualitative detection of point mutations within the genes KRAS, BRAF and PIK3CA from tissue DNA, Randox said.

The array is compatible for use with a range of genomic DNA samples including; cell lines, formalin-fixed, paraffin-embedded tissue and fresh/frozen tissue.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.